Analyzing Aurinia Pharmaceuticals (NASDAQ:AUPH) & Coya Therapeutics (NASDAQ:COYA)

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Coya Therapeutics (NASDAQ:COYA) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Profitability

This table compares Aurinia Pharmaceuticals and Coya Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	97.68%	22.99%	17.99%
Coya Therapeutics	-643.44%	-71.48%	-63.57%

Earnings & Valuation

This table compares Aurinia Pharmaceuticals and Coya Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05 million	7.67	$287.20 million	$2.29	7.08
Coya Therapeutics	$7.95 million	9.65	-$21.23 million	($1.39)	-2.35

Aurinia Pharmaceuticals has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Aurinia Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Coya Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Institutional and Insider Ownership

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Aurinia Pharmaceuticals and Coya Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	3	2	1	2.67
Coya Therapeutics	1	0	5	0	2.67

Aurinia Pharmaceuticals currently has a consensus price target of $17.33, suggesting a potential upside of 6.93%. Coya Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 358.72%. Given Coya Therapeutics’ higher possible upside, analysts plainly believe Coya Therapeutics is more favorable than Aurinia Pharmaceuticals.

Summary

Aurinia Pharmaceuticals beats Coya Therapeutics on 10 of the 14 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.

About Coya Therapeutics

Coya Therapeutics is a clinical-stage biotechnology company developing therapies that aim to enhance the function of regulatory T cells, immune cells that help control inflammation. Its research focuses on potential treatments for neurodegenerative and other diseases associated with inflammation and immune dysfunction. The company’s development programs include biologic and cell-based approaches, with candidates under investigation for conditions including amyotrophic lateral sclerosis (ALS). These therapies remain in development; Coya does not have an approved commercial product.